TR-1: Standard form for notification of major holdings

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ :				Immupharma plc		
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)						
Non-UK issuer						
2. Reason for the no	tification (please mark	the appropriate	box or l	boxes with an "X")		
An acquisition or dis	posal of voting rights					Х
An acquisition or dis	posal of financial inst	ruments				
An event changing t	he breakdown of voti	ng rights				
Other (please speci	fy) ⁱⁱⁱ :					
3. Details of person	subject to the notifica	tion obligation	n ^{iv}			
Name			Lanstead Capital Investors LP			
City and country of	registered office (if ap	plicable)				
4. Full name of shar	reholder(s) (if different f	rom 3.) ^v				
Name						
City and country of registered office (if applicable)						
5. Date on which the threshold was crossed or reached ^{vi} :			18/12/2023			
6. Date on which issuer notified (DD/MM/YYYY):			19/12/2023			
7. Total positions of person(s) subject to the notification obligation						
	% of voting rights attached to shares (total of 8. A) (total of 8. B) 2)		ncial nts	Total of both in % (8.A + 8.B)	Total number of votin rights of issuer ^{vii}	ıg
Resulting situation on the date on which threshold was crossed or reached	17.99%	0.00%		17.99%	416,437,265	
Position of previous notification (if applicable)	21.93%	0.00%		21.93%		

A: Voting rights attached to shares					
Class/type of	Number of voting rig	ghts ^{ix}	% of voting rights		
shares ISIN code (if possible)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)	
Ordinary Shares ISIN: GB0033711010	74,933,721	0	17.99%	0.00%	

SUBTOTAL 8. A

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))				
Type of financial instrument	Expiration date ^x	Exercise/ Conversion Period ^{xi}	Number of voting rights that may be acquired if the instrument is exercised/converted.	% of voting rights
N/A				
	•	SUBTOTAL 8. B 1		

B 2: Financial I (DTR5.3.1.1 (b))		similar economic	effect according	to Art. 13(1)(b) of Di	rective 2004/109/EC
Type of financial instrument	Expiration date ^x	Exercise/ Conversion Period ^{xi}	Physical or cash settlement ^{xii}	Number of voting rights	% of voting rights
N/A					
			SUBTOTAL 8.B.2		

9. Information in relation applicable box with an "X")	to the person subject to the	notification obligation (plea	se mark the	
Person subject to the notific	ation obligation is not controlle	ed by any natural person or lec	al entity and does not	V
control any other undertakin	g(s) holding directly or indirect	ly an interest in the (underlyin	g) issuer ^{xiii}	Х
Full chain of controlled unde	rtakings through which the voti	ng rights and/or the		
financial instruments are effe (please add additional rows	ectively held starting with the u as necessary)	ltimate controlling natural pers	on or legal entity ^{xiv}	
Name ^{xv}	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equ is higher than the not threshold	
N/A				

10. In case of proxy voting, please identify:	
Name of the proxy holder	
The number and % of voting rights held	
The date until which the voting rights will be held	

11. Additional information ^{XVi}			

FIACE OF COMPLETION	LOIN
Date of completion	19/12/2023

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

HOLZKLFFXLLZFBV